Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Improved quality of life with erlotinib in a randomised phase III study
ENSURE, a randomised, phase III study, met its primary endpoint of improved progression-free survival (PFS) with erlotinib vs. gemcitabine/cisplatin in Asian patients with epidermal-growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).